HYPERION DEFI, INC. (HYPD) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-13.97M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | -2.10× | Operating cash flow / net income. Period ending 2026-06-30. $-13.97M ÷ $6.65M ≈ -2.10× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -13.97M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 1.40M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 6.65M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-13.97M | (m) | (m) | $1.40M | (m) | $6.65M | (m) | (m) | (m) | -2.10× |
| 2026-03-31 | (m) | (m) | $-14.52M | (m) | (m) | $1.04M | (m) | $-32.99M | (m) | (m) | (m) | 0.44× |
| 2025-12-31 | (m) | (m) | $-14.77M | (m) | (m) | $813.46K | (m) | $-45.31M | (m) | (m) | (m) | 0.33× |
| 2025-09-30 | (m) | (m) | $-16.82M | (m) | (m) | $345.32K | (m) | $-25.50M | (m) | (m) | (m) | 0.66× |
| 2025-06-30 | $-19.97M | (m) | $-19.94M | $24.58K | (m) | $44.44K | (m) | $-40.02M | (m) | (m) | -44937.07% | 0.50× |
| 2025-03-31 | (m) | (m) | $-24.67M | (m) | (m) | $67.06K | (m) | $-42.38M | (m) | (m) | (m) | 0.58× |
| 2024-12-31 | $-30.28M | (m) | $-30.12M | $161.48K | (m) | $57.34K | (m) | $-49.82M | (m) | (m) | -52815.78% | 0.60× |
| 2024-09-30 | $-30.64M | (m) | $-30.33M | $306.71K | (m) | $31.83K | (m) | $-37.83M | (m) | (m) | -96252.16% | 0.80× |
| 2024-06-30 | $-31.11M | (m) | $-30.23M | $885.25K | (m) | $31.41K | (m) | $-37.28M | (m) | (m) | -99075.11% | 0.81× |
| 2024-03-31 | $-28.81M | (m) | $-26.77M | $2.04M | (m) | (m) | (m) | $-32.44M | (m) | (m) | (m) | 0.83× |
| 2023-12-31 | $-26.68M | (m) | $-23.84M | $2.85M | (m) | $3.79K | (m) | $-27.26M | (m) | (m) | -704624.53% | 0.87× |
| 2023-09-30 | $-25.65M | (m) | $-22.92M | $2.73M | (m) | (m) | (m) | $-25.42M | (m) | (m) | (m) | 0.90× |
| 2023-06-30 | $-26.28M | (m) | $-23.90M | $2.38M | (m) | (m) | (m) | $-25.39M | (m) | (m) | (m) | 0.94× |
| 2023-03-31 | $-25.17M | (m) | $-23.88M | $1.29M | (m) | (m) | (m) | $-26.41M | (m) | (m) | (m) | 0.90× |
| 2022-12-31 | $-25.65M | (m) | $-25.11M | $540.36K | (m) | (m) | (m) | $-28.01M | (m) | (m) | (m) | 0.90× |
| 2022-09-30 | $-26.15M | (m) | $-25.58M | $570.88K | (m) | $10.00M | (m) | $-18.90M | (m) | (m) | -261.48% | 1.35× |
| 2022-06-30 | $-24.72M | (m) | $-23.85M | $860.17K | (m) | $10.00M | (m) | $-17.16M | (m) | (m) | -247.15% | 1.39× |
| 2022-03-31 | $-25.54M | (m) | $-24.48M | $1.06M | (m) | $12.00M | (m) | $-14.77M | (m) | (m) | -212.85% | 1.66× |
| 2021-12-31 | $-22.10M | (m) | $-20.87M | $1.23M | (m) | $14.00M | (m) | $-12.78M | (m) | (m) | -157.86% | 1.63× |
| 2021-09-30 | $-10.75M | (m) | $-9.53M | $1.22M | (m) | (m) | (m) | $-19.97M | (m) | (m) | (m) | 0.48× |
| 2021-06-30 | $-7.15M | (m) | $-6.37M | $776.76K | (m) | $6.00M | (m) | $-19.50M | (m) | (m) | -119.13% | 0.33× |
| 2021-03-31 | $-5.55M | (m) | $-5.04M | $511.65K | (m) | (m) | (m) | $-19.67M | (m) | (m) | (m) | 0.26× |
| 2020-12-31 | $-6.65M | (m) | $-6.38M | $261.26K | (m) | $2.00M | (m) | $-19.77M | (m) | (m) | -332.28% | 0.32× |
| 2020-09-30 | $-16.20M | (m) | $-15.87M | $325.21K | (m) | (m) | (m) | $-20.80M | (m) | (m) | (m) | 0.76× |
| 2020-06-30 | $-18.09M | (m) | $-17.80M | $298.89K | (m) | (m) | (m) | $-20.36M | (m) | (m) | (m) | 0.87× |
| 2020-03-31 | $-19.20M | (m) | $-18.94M | $260.57K | (m) | (m) | (m) | $-20.68M | (m) | (m) | (m) | 0.92× |
| 2019-12-31 | $-19.09M | (m) | $-18.92M | $166.64K | (m) | (m) | (m) | $-21.16M | (m) | (m) | (m) | 0.89× |
| 2019-09-30 | $-19.08M | (m) | $-19.00M | $71.39K | (m) | (m) | (m) | $-22.10M | (m) | (m) | (m) | 0.86× |
| 2019-06-30 | (m) | (m) | $-18.72M | (m) | (m) | (m) | (m) | $-21.77M | (m) | (m) | (m) | 0.86× |
| 2019-03-31 | (m) | (m) | $-16.62M | (m) | (m) | (m) | (m) | $-19.76M | (m) | (m) | (m) | 0.84× |
| 2018-12-31 | $-13.14M | (m) | $-13.11M | $27.91K | (m) | (m) | (m) | $-17.25M | (m) | (m) | (m) | 0.76× |
| 2018-09-30 | $-11.01M | (m) | $-11.00M | $6.97K | (m) | (m) | (m) | $-13.23M | (m) | (m) | (m) | 0.83× |
| 2018-06-30 | $-8.25M | (m) | $-8.25M | $0.00 | (m) | (m) | (m) | $-9.80M | (m) | (m) | (m) | 0.84× |
| 2018-03-31 | $-6.25M | (m) | $-6.25M | $-2.01K | (m) | (m) | (m) | $-7.45M | (m) | (m) | (m) | 0.84× |
| 2017-12-31 | $-4.74M | (m) | $-4.73M | $10.23K | (m) | (m) | (m) | $-5.13M | (m) | (m) | (m) | 0.92× |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-3.25M | (m) | $-3.20M | $43.12K | (m) | (m) | (m) | $-3.53M | (m) | (m) | (m) | 0.91× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |